Farnum Rhonda sold $218K of TBPH
Farnum Rhonda (SVP, COMM & MEDICAL AFFAIRS) sold 13,314 shares of Theravance Biopharma, Inc. (TBPH) at an average of $16.39 ($16.38–$16.39, $0.22M total) across 3 trades on 2026-06-15 under a Rule 10b5-1 trading plan.
How this was made
The 30-second read
Why it matters
The newest fact is the specific open-market sale amount, price range, and that it was executed under a pre-arranged 10b5-1 plan; no other company developments are provided.
Market read
A planned insider sale is typically low-signal for fundamentals, but it can be used as a minor sentiment input.
What to watch
Traders may want to compare this sale size vs prior insider activity and whether other executives also sell around the same window.
Background
The article is an SEC Form 4 insider transaction disclosure for Theravance Biopharma, Inc.
Ticker impact
Insider Form 4 shows SVP Farnum Rhonda sold 13,314 shares of Theravance Biopharma at ~$16.3863 via a 10b5-1 plan.
Low near-term impact; any reaction is likely muted unless follow-on selling accelerates beyond planned activity.
The disclosure is an open-market sale under a pre-arranged 10b5-1 plan, with no accompanying operational/regulatory/clinical news in the text.
Market effects
No sector-level read-through; this is company-specific insider transaction data only.
None indicated.
None indicated.
Counterpoint
Even planned 10b5-1 sales can coincide with private information; if insiders repeatedly sell at similar sizes, it can still pressure sentiment.
Key entities
- issuerTheravance Biopharma, Inc.
Subject of the Form 4 insider sale disclosure (TBPH).
- insiderFarnum Rhonda
SVP, Commercial & Medical Affairs; sold 13,314 shares via open-market sale under a 10b5-1 plan.
